Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Cancundude

Rank: Treasurer [?]

Points: 1672 [?]

Votes: 30 Score: 2.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

Cancundude

posted on Dec 22, 2020 08:13AM

Oh forgot to add. To use the word "significantly" in the news release is not to be taken lightly. Pfizer and others might have to scoop this up just to protect their future revenue streams from the new vaccines. Not to mention this new mutation in England has got people very jumpy. Geez I am so ramped up I am going to skip my morning coffee.